Allyx sets Phase II plans in motion after Phase Ia results for Alzheimer’s drug
Allyx Therapeutics is planning a Phase II study to demonstrate proof of concept in Alzheimer’s disease with its lead drug…
Alzheimer’s disease
-
-
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
Pharma Technology Focus is now available on all devices. Read it for free here We look into the safety issues associated…
-
Find out about the foundation for the first drugs using microbiome bacteria in the latest issue of Pharma Technology Focus
Pharma Technology Focus is now available on all devices. Read it for free here. In this issue we find out…
-
Pharma Technology Focus – Issue 76
Pharma Technology Focus is now available on all devices. Read it for free here Significant progress has been made to roll…
-
Alzheon finds brain substance inhibits Alzheimer’s protein formation
Biopharmaceutical firm Alzheon has discovered an endogenous substance in the human brain that can block the formation of neurotoxic beta…
-
Alector raises $133m to advance Alzheimer’s disease drugs
Biotechnology firm Alector has raised $133m in a series E financing round to support further development of its clinical programmes…